Table 1.
NI | I | NI | I | NI | I | NI | I | NI | NI | NI | |
---|---|---|---|---|---|---|---|---|---|---|---|
HCAbs | 2F4 | 2F4 | 1F3 | 1F3 | 3A8 | 3A8 | 4H1 | 4H1 | 7F2 | HC19 | X31 |
Concentration (mg/ml) | 0.85 | 0.9 | 1.2 | 1.2 | 0.48 | 0.55 | 1.6 | 0.8 | 0.4 | NK | NK |
X31(50% reduction) | 32 | 640 | >256 | >1,280 | 16 | 20 | 2 | 2 | 2 | 6,400 | 2,560 |
X31 (any visible reduction) | 64 | >1,280 | >256 | >1,280 | 64 | 160 | 2 | 8 | 64 | >12,800 | >5,120 |
The numbers show best neutralizing capacity for 1F3 HCAb at ≥0.9 μg/ml (~11nM), followed by 2F4 at 1.4 µg/ml (~18nM).
NI, not preincubated with the virus; I, preincubated with the virus; NK, not known; neutralization titer, reciprocal of the 50% plaque reduction.